There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Compared to other anti-diabetic drugs, semaglutide, also known as Ozempic, may lower the risk of Alzheimer’s disease in ...

Polypharmacy, commonly defined as taking five or more medications daily, is a significant health care concern impacting over ...

Find out what AI has already brought to Alzheimer's disease research and most importantly, what it can accomplish in the ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

Researchers have discovered that methazolamide, a glaucoma drug, can clear tau protein build-up in the brain, a key factor in ...

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

"Of course, these findings are purely associative and do not prove that sleep apnea causes dementia. That would likely ...

A common yet underdiagnosed sleep disorder contributes to the development of dementia among adults -; particularly women, a ...

People are spending nearly an hour less each day doing activities outside the home, researchers reported. Health News // 1 ...

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...